AI research is central to many of the deals. In April, French pharmaceutical giant Sanofi announced a $1.7 billion agreement ...

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

AstraZeneca (NASDAQ:AZN) is looking to boost its cardiovascular pipeline through an exclusive license agreement with CSPC Pharmaceutical Group (CSPC). As part of the deal, AstraZeneca will pay ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

CSPC said the compound was discovered by the Group's AI-driven small molecule drug design platform. AstraZeneca's London-listed shares slipped 0.2% on Monday but have gained 11% this year.

AstraZeneca teams up with CSPC in a $1.92 billion deal to develop YS2302018, a novel Lp (a) disruptor aimed at treating cardiovascular disease. Airsupra, AstraZeneca's asthma drug, shows promise ...

AstraZeneca said it would have access to CSPC's pre-clinical candidate small molecule - YS2302018 - an oral Lp (a) disruptor, with the aim to develop it as a lipid-lowering therapy.

AstraZeneca has licensed a small-molecule lipoprotein disruptor from China’s CSPC Pharmaceutical Group for $100 million. The molecule is intended to prevent formation of lipoprotein(a), high ...

0347 ET – CSPC Pharmaceutical looks set to benefit from an exclusive licensing agreement with AstraZeneca to develop and commercialize a pre-clinical lipid-lowering drug compound, Nomura ...

AstraZeneca aims to hit that key protein target with an oral small molecule licensed from CSPC Pharmaceutical Group. By Frank Vinluan ...

AstraZeneca (NASDAQ: AZN) is looking to boost its cardiovascular pipeline through an exclusive license agreement with CSPC Pharmaceutical Group (CSPC). As part of the deal, AstraZeneca will pay ...